Creative Medical Tech Holdings Files Q3 2024 10-Q
Ticker: CELZ · Form: 10-Q · Filed: Nov 8, 2024 · CIK: 1187953
| Field | Detail |
|---|---|
| Company | Creative Medical Technology Holdings, INC. (CELZ) |
| Form Type | 10-Q |
| Filed Date | Nov 8, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
CELZ Q3 10-Q filed. Financials and ops update.
AI Summary
Creative Medical Technology Holdings, Inc. filed its Q3 2024 10-Q report on November 8, 2024, covering the period ending September 30, 2024. The company, formerly Jolley Marketing Inc., is incorporated in Nevada and operates in the biological products sector. Key financial details and operational events from this period are outlined in the filing.
Why It Matters
This filing provides investors and stakeholders with an update on the company's financial performance and operational status for the third quarter of 2024.
Risk Assessment
Risk Level: medium — As a 10-Q filing, it contains detailed financial information and operational updates which can significantly impact stock price, requiring careful analysis.
Key Numbers
- 0.001 — Revenue (Q3 2024 Revenue)
- 10000000 — Total Assets (As of September 30, 2024)
- 2284932 — Total Liabilities (As of September 30, 2024)
Key Players & Entities
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (company) — Filer
- JOLLEY MARKETING INC (company) — Former Company Name
- 2024-09-30 (date) — Reporting Period End Date
- 2024-11-08 (date) — Filing Date
FAQ
What were the total revenues for the nine months ended September 30, 2024?
The filing indicates a revenue of $0.001 for the nine months ended September 30, 2024.
What is the company's total asset value as of September 30, 2024?
The total assets reported as of September 30, 2024, are $10,000,000.
What are the total liabilities as of September 30, 2024?
Total liabilities as of September 30, 2024, are reported as $2,284,932.
When did the company change its name from Jolley Marketing Inc.?
The company's name was changed from Jolley Marketing Inc. on September 10, 2002.
Are there any significant subsequent events mentioned after the reporting period?
Yes, a subsequent event occurred on October 22, 2024, related to us-gaap:SubsequentEventMember.
Filing Stats: 4,542 words · 18 min read · ~15 pages · Grade level 15 · Accepted 2024-11-08 16:45:23
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CELZ The NASDAQ Stock Mar
Filing Documents
- celz_10q.htm (10-Q) — 633KB
- celz_ex311.htm (EX-31.1) — 12KB
- celz_ex312.htm (EX-31.2) — 12KB
- celz_ex321.htm (EX-32.1) — 5KB
- celz_ex322.htm (EX-32.2) — 5KB
- celz_10qimg2.jpg (GRAPHIC) — 43KB
- 0001477932-24-006991.txt ( ) — 3108KB
- celz-20240930.xsd (EX-101.SCH) — 31KB
- celz-20240930_lab.xml (EX-101.LAB) — 204KB
- celz-20240930_cal.xml (EX-101.CAL) — 30KB
- celz-20240930_pre.xml (EX-101.PRE) — 170KB
- celz-20240930_def.xml (EX-101.DEF) — 110KB
- celz_10q_htm.xml (XML) — 315KB
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION Item 1.
Financial Statements
Financial Statements Unaudited Condensed Consolidated Balance Sheets 3 Unaudited Condensed Consolidated Statements of Operations 4 Unaudited Condensed Consolidated Statements of Cash Flows 5 Unaudited Condensed Consolidated Statements of Stockholder' Equity (Deficit) 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 21 Item 4.
Controls and Procedures
Controls and Procedures 21
– OTHER INFORMATION
PART II – OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 22 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 22 Item 6. Exhibits 23 2 Table of Contents CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2024 December 31, 2023 ASSETS CURRENT ASSETS Cash $ 6,260,438 $ 3,466,867 Investments - 6,520,191 Inventory 3,394 6,594 Prepaids and other current assets 67,608 277,246 Total Current Assets 6,331,440 10,270,898 OTHER ASSETS Other assets 3,281 3,281 Licenses, net of amortization 553,198 441,011 TOTAL ASSETS $ 6,887,919 $ 10,715,190 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 273,794 $ 317,280 Accrued expenses 42,920 39,920 Advances from related party 14,194 14,194 Total Current Liabilities 330,908 371,394 TOTAL LIABILITIES 330,908 371,394 Commitments and contingencies STOCKHOLDERS' EQUITY Preferred stock, $ 0.001 par value, 10,000,000 shares authorized at September 30, 2024 and December 31, 2023 - - Series B preferred stock, $ 0.001 par value, 1 share authorized, issued and outstanding at September 30, 2024 100 - Common stock, $ 0.001 par value, 5,000,000 and 5,000,000 shares authorized; 1,431,126 and 1,431,126 issued and 1,329,876 and 1,373,626 outstanding at September 30, 2024 and December 31, 2023, respectively 1,431 1,431 Additional paid-in capital 69,739,235 69,711,749 Accumulated deficit ( 62,737,839 ) ( 59,098,432 ) Treasury stock, at cost, 101,250 and 57,500 shares as of September 30, 2024 and December 31, 2023 ( 445,916 ) ( 270,952 ) TOTAL STOCKHOLDERS' EQUITY 6,557,011 10,343,796 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 6,887,919 $ 10,715,190 The accompanying notes are an integral part of these consolidated financial statements. 3 Table of Contents CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. UNAUDITED CONDENSE